WINTWWindtree Therapeutics, Inc.

About Windtree Therapeutics, Inc. (WINTW)

Windtree Therapeutics, Inc. (WINTW) is a Biotechnology company headquartered in Warrington, PA, United States whose shares trade over-the-counter on the Pink tier.

A clinical-stage biopharmaceutical and device company focused on developing novel therapies for acute cardiovascular and pulmonary diseases. Windtree's lead product candidates are being developed to treat acute heart failure and respiratory distress syndrome in premature infants.

WINTW key facts

Ticker symbol

WINTW

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Warrington, PA, United States

Country of incorporation

US

Year of incorporation

1992

Employees

28

Estimated market cap

$28.7K (as of May 14, 2025)

Shares outstanding

4,780,437

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Windtree Therapeutics, Inc. leadership

• Craig E. Fraser — CEO, President
• Eric Curtis — COO
• John A. Tattory — CFO, Senior VP
• Mary B. Templeton, Esq. — Senior VP, General Counsel, Corporate Secretary
• Steven G. Simonson, MD — Senior VP, Chief Med. Officer
• Kathryn A. Cole — VP, Human Res., Senior VP
• George Cox — VP, Tech. Svcs.
• Lawrence A. Weinstein — Vice President

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with W